🔎 Trials Near Me

Home › Coronary Artery Disease › NCT03217006

Randomization of Single vs Multiple Arterial Grafts

Recruiting

Randomized Comparison of the Clinical Outcome of Single Versus Multiple Arterial Grafts: the ROMA Trial

Who can join

Ages 18 to 70 · All sexes

Full eligibility criteria
Inclusion Criteria:

* Primary isolated CABG patients with disease of the left main coronary artery and/or of the left anterior descending and the circumflex coronary system with or without disease of the right coronary artery.

Exclusion Criteria:

* Age \> 70 years
* Single graft
* Emergency operation
* Evolving myocardial infarction within 48 hours of surgery
* Left ventricular ejection fraction of \< 35%
* Any concomitant cardiac or non-cardiac procedure
* Previous cardiac surgery
* Preoperative severe end-organ dysfunction (dialysis, liver failure, respiratory failure), cancer or any co-morbidity that reduce life expectancy to less than 5 years.
* Inability to use the saphenous vein or to use both radial and right internal thoracic arteries
* Anticipated need for coronary thrombo-endarterectomy
* Planned hybrid revascularization

About the study

The primary hypothesis of ROMA is that in patients undergoing primary isolated non-emergent coronary artery bypass surgery (CABG), the use of two or more arterial grafts compared to a single arterial graft is associated with a reduction in the composite outcome of death from any cause, any stroke, post discharge myocardial infarction and/or repeat revascularization. The secondary hypothesis is that in patients undergoing primary isolated non-emergent CABG, the use of two or more arterial grafts compared to a single arterial graft is associated with improved survival.

Prospective event-driven unblinded randomized multicenter trial of at least 4,300 subjects enrolled in at least 25 international centers. Patients will be randomized to a single arterial graft (SAG) or multiple arterial grafts (MAG). Patients will be randomized in a 1:1 fashion between the two groups. Permuted block randomization with random blocks stratified by the center and the type of second arterial graft will be used to provide treatment distribution in equal proportion.

What is being tested

Sponsor: Weill Medical College of Cornell University · Participants: 4,300 · Started: Jan 7, 2018

Contact the study team

Official record on ClinicalTrials.gov — NCT03217006

Locations in the U.S.

ColoradoUniversity of Colorado, Boulder
MassachusettsBaystate Health, Springfield
NebraskaNebraska Heart Hospital, Lincoln
University of Nebraska Medical Center, Omaha
New YorkNewYork-Presbyterian Brooklyn Methodist Hospital, Brooklyn
Icahn School of Medicine, Mount Sinai, New York
Lenox Hill Hospital (Northwell), New York
NewYork-Presbyterian Queens, New York
Weil Cornell Medical College Department of Cardiothoracic Surgery, New York
OhioCleveland Clinic Foundation, Cleveland
PennsylvaniaAllegheny General Hospital (Cardiovascular Institute), Pittsburgh

Conditions

From ClinicalTrials.gov, data retrieved Sep 29, 2026. Each study sets its own eligibility; the study team decides who can join.